Future identification of key targets leading to the broad phenotypic response in the combination, in contrast to the targets of each drug as a single agent, may allow the development of novel combinatorial therapies with clinical efficacy against CMM independent of the tumor’s BRAF/NRAS oncogenic mutational status. The gene discussed is NRAS; the disease is neoplasm.